Literature DB >> 17656585

Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses.

Qing Xia1, Jessica Radzio, Karen S Anderson, Nicolas Sluis-Cremer.   

Abstract

Nonnucleoside reverse transcriptase inhibitors (NNRTI) are a group of structurally diverse compounds that bind to a single site in HIV-1 reverse transcriptase (RT), termed the NNRTI-binding pocket (NNRTI-BP). NNRTI binding to RT induces conformational changes in the enzyme that affect key elements of the polymerase active site and also the association between the two protein subunits. To determine which conformational changes contribute to the mechanism of inhibition of HIV-1 reverse transcription, we used transient kinetic analyses to probe the catalytic events that occur directly at the enzyme's polymerase active site when the NNRTI-BP was occupied by nevirapine, efavirenz, or delavirdine. Our results demonstrate that all NNRTI-RT-template/primer (NNRTI-RT-T/P) complexes displayed a metal-dependent increase in dNTP binding affinity (K(d) ) and a metal-independent decrease in the maximum rate of dNTP incorporation (k (pol)). The magnitude of the decrease in k (pol) was dependent on the NNRTI used in the assay: Efavirenz caused the largest decrease followed by delavirdine and then nevirapine. Analyses that were designed to probe direct effects on phosphodiester bond formation suggested that the NNRTI mediate their effects on the chemistry step of the DNA polymerization reaction via an indirect manner. Because each of the NNRTI analyzed in this study exerted largely similar phenotypic effects on single nucleotide addition reactions, whereas each of them are known to exert differential effects on RT dimerization, we conclude that the NNRTI effects on subunit association do not directly contribute to the kinetic mechanism of inhibition of DNA polymerization.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17656585      PMCID: PMC2203366          DOI: 10.1110/ps.072829007

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  37 in total

1.  Dissection of a metal-ion-mediated conformational change in Tetrahymena ribozyme catalysis.

Authors:  Shu-ou Shan; Daniel Herschlag
Journal:  RNA       Date:  2002-07       Impact factor: 4.942

Review 2.  Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules.

Authors:  Nicolas Sluis-Cremer; Gilda Tachedjian
Journal:  Eur J Biochem       Date:  2002-11

3.  Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis.

Authors:  Adrian S Ray; Eisuke Murakami; Aravind Basavapathruni; Joseph A Vaccaro; Dagny Ulrich; Chung K Chu; Raymond F Schinazi; Karen S Anderson
Journal:  Biochemistry       Date:  2003-07-29       Impact factor: 3.162

Review 4.  Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding.

Authors:  Nicolas Sluis-Cremer; N Alpay Temiz; Ivet Bahar
Journal:  Curr HIV Res       Date:  2004-10       Impact factor: 1.581

5.  Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase.

Authors:  G Tachedjian; M Orlova; S G Sarafianos; E Arnold; S P Goff
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

6.  Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor.

Authors:  R M Esnouf; J Ren; A L Hopkins; C K Ross; E Y Jones; D K Stammers; D I Stuart
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

7.  Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms.

Authors:  Y Hsiou; J Ding; K Das; A D Clark; S H Hughes; E Arnold
Journal:  Structure       Date:  1996-07-15       Impact factor: 5.006

8.  Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance.

Authors:  H Huang; R Chopra; G L Verdine; S C Harrison
Journal:  Science       Date:  1998-11-27       Impact factor: 47.728

9.  Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 A resolution.

Authors:  J Ding; K Das; Y Hsiou; S G Sarafianos; A D Clark; A Jacobo-Molina; C Tantillo; S H Hughes; E Arnold
Journal:  J Mol Biol       Date:  1998-12-11       Impact factor: 5.469

10.  L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase.

Authors:  S D Young; S F Britcher; L O Tran; L S Payne; W C Lumma; T A Lyle; J R Huff; P S Anderson; D B Olsen; S S Carroll
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

View more
  27 in total

1.  Synthesis and Anti-HIV-1 Activity of a Novel Series of Aminoimidazole Analogs.

Authors:  Swastika Ganguly; Sankaran Murugesan; Naru Prasanthi; Onur Alptürk; Brian Herman; Nicolas Sluis-Cremer
Journal:  Lett Drug Des Discov       Date:  2010-06-01       Impact factor: 1.150

2.  N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation.

Authors:  Mia J Biondi; Greg L Beilhartz; Suzanne McCormick; Matthias Götte
Journal:  J Biol Chem       Date:  2010-06-08       Impact factor: 5.157

3.  Double Variational Binding--(SMILES) Conformational Analysis by Docking Mechanisms for Anti-HIV Pyrimidine Ligands.

Authors:  Mihai V Putz; Nicoleta A Dudaș; Adriana Isvoran
Journal:  Int J Mol Sci       Date:  2015-08-18       Impact factor: 5.923

4.  Protein-mediated antagonism between HIV reverse transcriptase ligands nevirapine and MgATP.

Authors:  Xunhai Zheng; Geoffrey A Mueller; Eugene F DeRose; Robert E London
Journal:  Biophys J       Date:  2013-06-18       Impact factor: 4.033

5.  Antileishmanial activity of antiretroviral drugs combined with miltefosine.

Authors:  Sonya Costa; Marisa Machado; Cláudia Cavadas; Maria do Céu Sousa
Journal:  Parasitol Res       Date:  2016-06-01       Impact factor: 2.289

6.  A cell-based strategy to assess intrinsic inhibition efficiencies of HIV-1 reverse transcriptase inhibitors.

Authors:  Michael E Abram; Manuel Tsiang; Kirsten L White; Christian Callebaut; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

7.  A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.

Authors:  Galina N Nikolenko; Krista A Delviks-Frankenberry; Vinay K Pathak
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

8.  Crystal structures of HIV-1 reverse transcriptase with picomolar inhibitors reveal key interactions for drug design.

Authors:  Kathleen M Frey; Mariela Bollini; Andrea C Mislak; José A Cisneros; Ricardo Gallardo-Macias; William L Jorgensen; Karen S Anderson
Journal:  J Am Chem Soc       Date:  2012-11-19       Impact factor: 15.419

9.  Molecular docking and 3D-QSAR studies on triazolinone and pyridazinone, non-nucleoside inhibitor of HIV-1 reverse transcriptase.

Authors:  Sree Kanth Sivan; Vijjulatha Manga
Journal:  J Mol Model       Date:  2009-12-15       Impact factor: 1.810

Review 10.  HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.

Authors:  Kalyan Das; Eddy Arnold
Journal:  Curr Opin Virol       Date:  2013-04-19       Impact factor: 7.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.